Research Article

Modeling Drug-Carrier Interaction in the Drug Release from Nanocarriers

Table 2

Parameter estimates for simulations in Figure 4.

Drug/CarrieraMechanismsVariablesModel parametersb
(10−21J)

Pore size12.9 nm0.192M
Telmisartan MSNP [30]7.8 nm0.1M
3.6 nm0.0652M

Amine additiveno additive3.913D0.013D5.11
Retinoid Am80PEG-PBLA [11]TPA7.314D0.067D6.84
DMDA1.272D0.059D6.61
DMOA0.541D0.001D−1.18

Medium ion strength0.15 M NaCl0.381H0.023H3.36
DSPLNP [10]15 mM NaCl0.248H0.001H4.90
0.5 mM NaCl0.258H0.012H0.64
DDI water0.237H0.005H−5.1

Copolymer compositionPLA/PGA 50 : 500.197D0.019D−1.69
Estradiol PLGA [12]PLA/PGA 65 : 350.163D0.004D−2.40
PLA/PGA 85 : 150.179D0.007D−3.94

Savoxepine PLA [13]Particle size303 nm1.437D0.064D−0.61
671 nm1.792D0.028D−5.52

Composition and molecular weightPLGA 8,0000.333D0.336D−1.06
Steroids PLA/PLGA [9]PLGA 13,0000.375D0.04D−1.56
PLA 9,0000.319D0.004D−3.2
PLA 14,0000.099D0.128D−6.73
Control (BDP)PLA 14,0005.576D0.344D−0.67

aMSNP: mesoporous silica nanoparticle; PEG-PBLA: polyethylene glycol-poly(benzyl L-aspartate); DMDA: N,N-dimethyldodecylamine; DMOA: N,N-dimethyloctadecylamine; TPA: triphenylamine; DS: dextran sulfate sodium; PLNPs: polymer-lipid hybrid nanoparticles; PLLA: poly(L-lactide).
b and have different units in difference cases: M: minute−1, H: hour−1, and D: day−1.